Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer

Crossject, a specialty pharmaceutical company, announced the appointment of Dan Chiche, MD, as Chief Medical Officer, North America. Dr. Chiche will bring his expertise in drug development to strengthen Crossject's presence in the United States.

With twenty years of experience in leading companies such as Glaxo and Bristol Myers Squibb, Dr. Chiche has participated in key projects in various medical fields. His primary mission will include overseeing the regulatory registrations of ZEPIZURE® in the United States, an innovative treatment for epileptic seizures, planned for 2025.

Patrick Alexandre, Managing Director of Crossject, says this appointment is a crucial step for the company, strengthening their management team and their presence in North America.